Teva Retains Simvastatin Share As New Entrants Struggle To Meet Demand
Executive Summary
Generic companies may find it difficult to assess how much supply to produce when a large product loses 180-day exclusivity, comments by Teva Pharmaceuticals USA CEO William Marth suggest
You may also be interested in...
Generic Drug Service, Not Pricing, Is Key Performance Factor – Lehman’s Silver
The success of generic companies will be determined more by the breadth and quality of their offerings than product pricing, Lehman Brothers Senior VP-Specialty Pharmaceutical Research Rich Silver told the Generic Pharmaceutical Association
Generic Drug Service, Not Pricing, Is Key Performance Factor – Lehman’s Silver
The success of generic companies will be determined more by the breadth and quality of their offerings than product pricing, Lehman Brothers Senior VP-Specialty Pharmaceutical Research Rich Silver told the Generic Pharmaceutical Association
Financial Analysts Roundtable Part II: Changes On Capitol Hill, FDA’s Risk Threshold And The Future Of The Cholesterol Market
The following excerpts are from a conversation "The Pink Sheet" had with three large cap pharmaceutical analysts, Prudential's Tim Anderson, Goldman Sachs' Jim Kelly and Morgan Stanley's Jami Rubin, concerning the outlook for the drug industry in 2007. 1Kelly and 2Rubin provided "The Pink Sheet" with extensive disclosure statements, which can be accessed by visiting 3www.ThePinkSheet.com. The 4first part of the series, which covered Medicare Part D, big pharma diversification, and the outlook for M&A, appeared in the Feb. 5 issue of "The Pink Sheet."